The infusion pump woes could have a broader impact on the Baxter brand name and impact sales in other segments if the problem is not resolved soon.
The recalling of thousands of COLLEAGUE and SYNDEO PCA infusion pumps by the FDA has cost Baxter over $170 million from 2005 - 2006.
Baxter pays it executives generously with money that could be invested towards increasing the firm's growth.